Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib in Relapsed/Refractory Nodal T Cell Lymphoma With TFH Phenotype
NCT06522737Phase 3Recruiting
- Sponsor
- Secura Bio
- Start
- May 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of duvelisib in nodal T-cell lymphoma, sponsored by Secura Bio. Started May 2025; status: recruiting.
02
Drugs
duvelisib
03
Conditions
nodal T-cell lymphoma
Beyond the preview
Go deeper on NCT06522737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522737.